Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $25.20.

Several equities research analysts recently commented on ALNA shares. Zacks Investment Research lowered shares of Allena Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 7th. Robert W. Baird assumed coverage on shares of Allena Pharmaceuticals in a research note on Friday, January 18th. They set an “outperform” rating and a $20.00 target price on the stock. B. Riley reaffirmed a “buy” rating and set a $22.00 target price on shares of Allena Pharmaceuticals in a research note on Friday, December 21st. ValuEngine cut shares of Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Wedbush reaffirmed a “buy” rating and set a $39.00 target price on shares of Allena Pharmaceuticals in a research note on Sunday, March 10th.

NASDAQ ALNA traded down $0.25 on Monday, hitting $6.35. The company had a trading volume of 10,062 shares, compared to its average volume of 39,807. The firm has a market cap of $132.18 million, a PE ratio of -3.69 and a beta of 1.87. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.19 and a current ratio of 11.19. Allena Pharmaceuticals has a 12-month low of $4.80 and a 12-month high of $17.26.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.04. On average, equities analysts predict that Allena Pharmaceuticals will post -1.88 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in ALNA. BlackRock Inc. increased its stake in Allena Pharmaceuticals by 1.7% in the third quarter. BlackRock Inc. now owns 577,443 shares of the company’s stock valued at $6,201,000 after purchasing an additional 9,736 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Allena Pharmaceuticals in the third quarter valued at approximately $116,000. Morgan Stanley boosted its holdings in shares of Allena Pharmaceuticals by 126.0% in the third quarter. Morgan Stanley now owns 1,856,640 shares of the company’s stock valued at $19,941,000 after acquiring an additional 1,034,990 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Allena Pharmaceuticals by 2.2% in the third quarter. Vanguard Group Inc. now owns 349,819 shares of the company’s stock valued at $3,757,000 after acquiring an additional 7,400 shares during the period. Finally, Vanguard Group Inc boosted its holdings in shares of Allena Pharmaceuticals by 2.2% in the third quarter. Vanguard Group Inc now owns 349,819 shares of the company’s stock valued at $3,757,000 after acquiring an additional 7,400 shares during the period. 80.06% of the stock is currently owned by institutional investors.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Story: FAANG Stocks

Analyst Recommendations for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.